Metformin Treatment for Multiple Sclerosis, Primary Progressive
Phase-Based Progress Estimates
Effectiveness
Safety
University of California, Los Angeles, Los Angeles, CA
Multiple Sclerosis, Primary Progressive+4 More
Metformin 500 Mg Oral Tablet, up to 4 tablets a day - DrugEligibility
18+
All Sexes
What conditions do you have?
Select
Eligibility
18+
All Sexes
What conditions do you have?
Select
Study Summary
The purpose of this study is to assess the safety of metformin for treatment of progressive multiple sclerosis
Eligible Conditions
- Multiple Sclerosis, Primary Progressive
- Secondary Progressive Multiple Sclerosis (SPMS)
Treatment Effectiveness
Effectiveness Progress
Other trials for Multiple Sclerosis, Primary Progressive
Study Objectives
3 Primary · 2 Secondary · Reporting Duration: between month 0 and month 12
Month 12
a reduction in localized cortical thinning on brain MRI between baseline and conclusion (month 0 and month 12)
a reduction in thalamic atrophy on brain MRI between baseline and conclusion (month 0 and month 12)
decrease in number of phase rimmed lesions between baseline and conclusion (month 0 and month 12)
decrease in plasma neurofilament light chain levels between baseline and conclusion (month 0 and month 12)
improvement in CVLT-II score between baseline and conclusion (month 0 and month 12)
improvement in PACC score between baseline and conclusion (month 0 and month 12)
improvement in PASAT score between baseline and conclusion (month 0 and month 12)
improvement in SDMT-oral score between baseline and conclusion (month 0 and month 12)
number of patients with adverse events between baseline and conclusion (month 0 and month 12)
number of patients with laboratory abnormalities between baseline and conclusion (month 0 and month 12)
number of patients with new T2 lesions on MRI from baseline to conclusion (month 0 and month 12)
preservation of ganglion cell inner plexiform layer density between baseline and conclusion (month 0 and month 12)
preservation of retinal nerve fiber layer density between baseline and conclusion (month 0 and month 12)
Trial Safety
Safety Progress
Other trials for Multiple Sclerosis, Primary Progressive
Trial Design
2 Treatment Groups
Metformin Treatment
1 of 2
Placebo Treatment
1 of 2
Experimental Treatment
Non-Treatment Group
44 Total Participants · 2 Treatment Groups
Primary Treatment: Metformin Treatment · Has Placebo Group · Phase < 1
Metformin Treatment
Drug
Experimental Group · 1 Intervention: Metformin 500 Mg Oral Tablet, up to 4 tablets a day · Intervention Types: DrugPlacebo Treatment
Drug
PlaceboComparator Group · 1 Intervention: Placebo oral tablet identical to metformin, up to 4 tablets a day · Intervention Types: DrugTrial Logistics
Trial Timeline
Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: between month 0 and month 12
Trial Background
Prof. Kevin Patel, Assistant Professor, Department of Neurology
Principal Investigator
University of California, Los Angeles
Closest Location: University of California, Los Angeles · Los Angeles, CA
2004First Recorded Clinical Trial
1 TrialsResearching Multiple Sclerosis, Primary Progressive
216 CompletedClinical Trials
Eligibility Criteria
Age 18+ · All Participants · 4 Total Inclusion Criteria
Mark “yes” if the following statements are true for you:You have a diagnosis of primary progressive multiple sclerosis or secondary progressive multiple sclerosis as defined by the 2017 McDonald Criteria.
About The Reviewer
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.
Popular Clinical Trials
Top Clinical Trials in Cities
Relevant Clinical Trials
Unbiased Results
We believe in providing patients with all the options.Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.Back to top
Conditions
Cancer Related
Treatments